RS64438B1 - Stabilne kompozicije semaglutida i njihova upotreba - Google Patents

Stabilne kompozicije semaglutida i njihova upotreba

Info

Publication number
RS64438B1
RS64438B1 RS20230658A RSP20230658A RS64438B1 RS 64438 B1 RS64438 B1 RS 64438B1 RS 20230658 A RS20230658 A RS 20230658A RS P20230658 A RSP20230658 A RS P20230658A RS 64438 B1 RS64438 B1 RS 64438B1
Authority
RS
Serbia
Prior art keywords
stable
semaglutide compositions
semaglutide
compositions
stable semaglutide
Prior art date
Application number
RS20230658A
Other languages
English (en)
Inventor
Dorthe Kot Engelund
Søren Skov Jensen
Joakim Lundqvist
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68503076&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS64438(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of RS64438B1 publication Critical patent/RS64438B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
RS20230658A 2018-10-26 2019-10-25 Stabilne kompozicije semaglutida i njihova upotreba RS64438B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP18202801 2018-10-26
EP19158226 2019-02-20
PCT/EP2019/079214 WO2020084126A1 (en) 2018-10-26 2019-10-25 Stable semaglutide compositions and uses thereof
EP19801228.8A EP3870213B1 (en) 2018-10-26 2019-10-25 Stable semaglutide compositions and uses thereof

Publications (1)

Publication Number Publication Date
RS64438B1 true RS64438B1 (sr) 2023-09-29

Family

ID=68503076

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20230658A RS64438B1 (sr) 2018-10-26 2019-10-25 Stabilne kompozicije semaglutida i njihova upotreba

Country Status (21)

Country Link
US (1) US20210379159A1 (sr)
EP (1) EP3870213B1 (sr)
JP (1) JP7422754B2 (sr)
KR (1) KR20210087465A (sr)
CN (1) CN112912100A (sr)
AU (1) AU2019363725B2 (sr)
BR (1) BR112021006598A2 (sr)
CA (1) CA3116271A1 (sr)
CL (1) CL2021000938A1 (sr)
CO (1) CO2021005915A2 (sr)
ES (1) ES2954584T3 (sr)
HR (1) HRP20230929T1 (sr)
HU (1) HUE062893T2 (sr)
IL (1) IL281938B2 (sr)
MX (1) MX2021004331A (sr)
PE (1) PE20211492A1 (sr)
PH (1) PH12021550705A1 (sr)
PL (1) PL3870213T3 (sr)
RS (1) RS64438B1 (sr)
SG (1) SG11202103137WA (sr)
WO (1) WO2020084126A1 (sr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3116271A1 (en) 2018-10-26 2020-04-30 Novo Nordisk A/S Stable semaglutide compositions and uses thereof
WO2021105393A1 (en) * 2019-11-29 2021-06-03 Novo Nordisk A/S Processes for obtaining stable glp-1 compositions
AU2021207313A1 (en) 2020-02-18 2022-07-28 Novo Nordisk A/S Pharmaceutical formulations
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
CN118103391A (zh) * 2021-11-12 2024-05-28 福建盛迪医药有限公司 Glp-1受体和gip受体双重激动剂的药物组合物及其用途
CN114660214B (zh) * 2022-02-18 2024-04-05 兰州积石药业有限公司 一种司美格鲁肽的液相色谱检测方法及其应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK136492D0 (da) * 1992-11-10 1992-11-10 Novo Nordisk As A pharmaceutical formulation
DE69232847T2 (de) 1991-12-20 2003-09-11 Novo Nordisk As Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält
ES2230727T3 (es) 1997-11-12 2005-05-01 Alza Corporation Procedimiento de administracion dermal de polipeptidos.
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
US20030119734A1 (en) 2001-06-28 2003-06-26 Flink James M. Stable formulation of modified GLP-1
US20060287221A1 (en) * 2003-11-13 2006-12-21 Novo Nordisk A/S Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
PT3300721T (pt) 2003-11-20 2019-06-06 Novo Nordisk As Formulações peptidicas contendo propileno glicol que sao ideais para a produção e para utilizacao em dispositivos de injeção
WO2006029634A2 (en) * 2004-09-17 2006-03-23 Novo Nordisk A/S Pharmaceutical compositions containing insulin and insulinotropic peptide
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
EP2036539A1 (en) * 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
WO2011109787A1 (en) * 2010-03-05 2011-09-09 Conjuchem, Llc Methods of administering insulinotropic peptides
JP5902194B2 (ja) 2010-12-16 2016-04-13 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニストとｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩とを含む固形組成物
US20120208755A1 (en) * 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2013127779A1 (en) 2012-03-01 2013-09-06 Novo Nordisk A/S Glp-1 prodrugs
ES2952874T3 (es) 2012-03-22 2023-11-06 Novo Nordisk As Composiciones de péptidos GLP-1 y preparación de estas
CN103566354B (zh) * 2012-07-25 2017-12-05 江苏豪森药业集团有限公司 含有glp‑1类似物的衍生物或其可药用盐的药物组合物
US9956287B2 (en) * 2013-02-06 2018-05-01 Perosphere Inc. Stable glucagon formulations
JP2014214153A (ja) 2013-04-30 2014-11-17 ニプロ株式会社 水溶液製剤およびその製造方法
WO2016038521A1 (en) * 2014-09-08 2016-03-17 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of liraglutide
WO2016077220A1 (en) * 2014-11-10 2016-05-19 Mb2 Llc Gip/glp-1 co-agonist peptides for human administration
WO2016083499A1 (en) * 2014-11-27 2016-06-02 Novo Nordisk A/S Glp-1 derivatives and uses thereof
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
JP7221694B2 (ja) * 2016-04-28 2023-02-14 ノヴォ ノルディスク アー／エス 心血管状態におけるセマグルチド
CN107661288A (zh) * 2016-07-29 2018-02-06 江苏泰康生物医药有限公司 含有glp‑1 类似物融合蛋白的稳定液体制剂及其制备
CN107952064B (zh) * 2016-10-14 2023-10-20 江苏豪森药业集团有限公司 含有聚乙二醇洛塞那肽的药物制剂及其制备方法
CN108210890A (zh) * 2016-12-09 2018-06-29 江苏泰康生物医药有限公司 重组人胰高血糖素样肽-1类似物融合蛋白的新型稳定制剂
GB201621987D0 (en) * 2016-12-22 2017-02-08 Archer Virgil L See Archer Sheri A Arecor Ltd Novel composition
CA3116271A1 (en) 2018-10-26 2020-04-30 Novo Nordisk A/S Stable semaglutide compositions and uses thereof

Also Published As

Publication number Publication date
IL281938B1 (en) 2023-12-01
KR20210087465A (ko) 2021-07-12
JP2022505290A (ja) 2022-01-14
EP3870213A1 (en) 2021-09-01
PH12021550705A1 (en) 2021-11-03
SG11202103137WA (en) 2021-04-29
IL281938A (en) 2021-05-31
BR112021006598A2 (pt) 2021-07-06
PL3870213T3 (pl) 2023-11-20
IL281938B2 (en) 2024-04-01
CN112912100A (zh) 2021-06-04
MX2021004331A (es) 2021-05-27
AU2019363725B2 (en) 2024-05-02
PE20211492A1 (es) 2021-08-11
CA3116271A1 (en) 2020-04-30
HRP20230929T1 (hr) 2023-11-24
EP3870213B1 (en) 2023-06-07
EP3870213C0 (en) 2023-06-07
ES2954584T3 (es) 2023-11-23
AU2019363725A1 (en) 2021-05-20
JP7422754B2 (ja) 2024-01-26
CL2021000938A1 (es) 2021-09-10
CO2021005915A2 (es) 2021-08-09
WO2020084126A1 (en) 2020-04-30
HUE062893T2 (hu) 2023-12-28
US20210379159A1 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
IL279897A (en) Fusosome preparations and their uses
SG11202011015QA (en) Fusosome compositions and uses thereof
IL271275A (en) Preparations containing coronas and their uses
IL272232A (en) GLP-1 compounds and their uses
IL281938A (en) Stable compositions of semaglutide and uses thereof
IL279755A (en) Senolytic preparations and their uses
IL277663A (en) Arunumab preparations and their uses
GB201807576D0 (en) Compositions and uses thereof
IL277441A (en) Variants of LFA3 and their preparations and uses
GB201821138D0 (en) Compositions and uses thereof
GB201812334D0 (en) Compositions and uses thereof
GB201821144D0 (en) Compositions and uses thereof
GB201819493D0 (en) Compositions and uses thereof
GB201818495D0 (en) Compositions and uses thereof
GB201818375D0 (en) Compositions and uses thereof
GB201808907D0 (en) Compositions and uses thereof
GB201808858D0 (en) Compositions and uses thereof
GB201808321D0 (en) Compositions and uses thereof
GB201808298D0 (en) Compositions and uses thereof
GB201805322D0 (en) Compositions and uses thereof
GB201805097D0 (en) Compositions and uses thereof
GB201805098D0 (en) Compositions and uses thereof
GB201805093D0 (en) Compositions and uses thereof
GB201804407D0 (en) Compositions and uses thereof
IL257226A (en) Compounds characterized by an inverse freezing property and their uses